Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | PI4KA | P42356 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.36 |
| ▸ | GCK | P35557 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 4/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | DHODH | Q02127 | 2/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12992181 | 0.90 | PIK3CA (0.40) | PIK3CAPIK3CDPIK3CBPI4KAPIK3CG | |
| SCHEMBL2711207 | 0.89 | ADORA2B (0.44) | PIK3CAPIK3CDPIK3CBPI4KAPIK3CG | |
| SCHEMBL2710885 | 0.86 | PTGES (0.40) | PDE10APTGESSYK | |
| SCHEMBL2710993 | 0.83 | CYP11B2 (0.35) | PIK3CAPIK3CDADORA2BSYKDHODH | |
| SCHEMBL249053 | 0.83 | DHODH (0.37) | PIK3CAPIK3CDPIK3CBPI4KAPIK3CG | |
| SCHEMBL2711227 | 0.80 | DHODH (0.39) | PIK3CAPIK3CDPIK3CBPI4KAPIK3CG | |
| SCHEMBL2712393 | 0.80 | ADK (0.40) | SYK | |
| SCHEMBL13019225 | 0.80 | AAK1 (0.33) | PIK3CAPIK3CDDHODHAAK1 | |
| SCHEMBL2711862 | 0.76 | CNR2 (0.46) | PIK3CASYK | |
| SCHEMBL2713622 | 0.76 | MAPK14 (0.38) | PIK3CADHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445886-B1 | 4-AMINOQUINOLINE DERIVATIVES AS PI3K INHIBITORS | AMGEN INC (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2445886-B1 | 4-AMINOQUINOLINE DERIVATIVES AS PI3K INHIBITORS | AMGEN INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-8940724-B2 | Quinoline derivitives and their uses | AMGEN INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940724-B2 | Quinoline derivitives and their uses | AMGEN INC. (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2445886-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen, Inc (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| WO-2010151791-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010151791-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | PIK3CA 29/4885PIK3CD 14/4885PIK3CB 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.